By Kailyn Rhone
Oncternal Therapeutics plans to cut its workforce by Dec. 2, leaving only four employees in part-time roles as the company explores strategic options.
As of March 1, the clinical-stage biopharmaceutical company had 27 full-time employees, three part-time employees, and several consultants. The decision to reduce its jobs was approved by its board on Nov. 13.
The San Diego-based company expects to incur around $2.4 million in costs related to severance, benefits and termination expenses. The charges will be primarily recorded in the fourth quarter.
Oncternal anticipates to complete the job reduction by year-end.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
November 14, 2024 18:15 ET (23:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。